Background: Metabolomic analysis using blood samples has been suggested to be use-
| INTRODUCTION
Primary liver tumors are relatively rare, accounting for 0.6% to 1.3% 1 of all tumors in dogs. The most common primary liver tumor in dogs is hepatocellular carcinoma (HCC), [1] [2] [3] which is frequently found in older dogs. Although liver tumors generally cannot be diagnosed by clinical signs, blood examination, or abdominal radiography, they are easily detected using abdominal ultrasonography and computed tomography, resulting in an increase in the number of animals in which liver tumors are incidentally discovered at an advanced stage. 4 Unfortunately, advanced diagnostic imaging, including computed tomography, may not be readily accessible for use in dogs because of high cost;
need for sedation or anesthesia, which is not desirable for older dogs or those with advanced disease; and, modalities and limited availability of such equipment in veterinary facilities. In addition, current diagnostic imaging may not be able to distinguish malignant tumor from benign changes. Moreover, early detection of liver tumors in dogs using current diagnostic methods is still challenging. Therefore, development of a noninvasive diagnostic method with high sensitivity and specificity would be valuable for the early detection and classification of pathological conditions in the liver.
Metabolomics is a powerful method that allows for the analysis of all metabolites in a biological system. In this way, metabolic changes associated with homeostatic disturbances in individual pathological conditions can be identified. 5, 6 Recently, metabolomic analysis using peripheral blood or urine samples has been developed as a promising approach for identifying several diseases, including cancer. 7 The hypothesis underlying the detection and profiling of changes in metabolites is based on the expectation that they will offer new perspectives not only for the processes of disease development but also for the identification of diagnostic biomarkers. Moreover, metabolic variations may be indicative of the biochemical status associated with individual diseases. 
| Blood collection and processing
The dogs were fasted for 12 hours before blood collection. Venous blood was collected in heparin-containing tubes from control dogs and dogs diagnosed with HCC. Samples were collected preoperatively and 3 to 6 months postoperatively. After blood collection, the heparinized blood samples were centrifuged immediately at 1500g for 5 minutes at 4 C. After centrifugation, plasma was promptly removed and frozen at −80 C until PFAA measurement. On the day of PFAA measurement, frozen plasma was thawed, mixed with equal volumes of 5% (wt/vol) trichloroacetic acid, and centrifuged at 1000g for 15 minutes at 4 C to remove precipitated proteins and obtain the supernatant.
| PFAA measurement
Analysis of the PFAA concentrations from the dogs was performed using an automated high-performance liquid chromatography amino acid analyzer (L-8900; Hitachi, Tokyo, Japan). Amino acids were separated by ion exchange chromatography and detected spectrophotometrically after a post-column reaction with ninhydrin reagent. The concentrations of 21 naturally occurring amino acids (alanine, arginine, asparagine, citrulline, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, ornithine, phenylalanine, proline, serine, taurine, threonine, tryptophan, tyrosine, and valine) were measured in the analysis. The total amino acid (TAA) concentrations were calculated as the sum of the concentrations of these 21 amino acids.
All amino acid concentrations were expressed in nmol/mL.
Fischer's ratio is defined as the molar concentration ratio of total branched-chain amino acids (BCAAs), calculated as the sum of the leucine, valine, and isoleucine concentrations, to total aromatic amino acids (AAAs), calculated as the sum of the phenylalanine and tyrosine concentrations. This ratio was calculated from the PFAA concentrations, as was the branched-chain amino acids to tyrosine ratio (BTR), which is a simpler calculation and can be used instead of Fischer's ratio. 19, 20 These ratios were used to evaluate liver function and severity of liver damage, and decreases in these 2 variables can reflect increasing severity of liver damage. Pearson's and Spearman's correlation analyses were used to determine the relationship between significant PFAA concentrations of dogs with HCC and serum liver enzyme activities as well as lesion size.
Bonferroni correction was applied to account for multiple comparisons of PFAAs by ANOVA and Kruskal-Wallis test. Statistical analyses were performed using commercial software (JMP Pro, version 14.0.0; SAS Institute Inc, Cary, North Carolina). A value of P < .05 was considered statistically significant (P < .0024 after Bonferroni correction).
3 | RESULTS
| Dogs
During the study period, 46 dogs were identified with liver masses and were surgically treated. Of these, 26 dogs (13 males and 9 females)
were diagnosed with HCC, and 8 (3 males and 5 females) were diagnosed with benign liver diseases, including 3 with cholangiocellular adenoma, 2 with nodular hyperplasia, and 1 case each of portal vein hypoplasia, hepatic cyst, and hematoma. The other 12 dogs were excluded from the study because of histopathologic results indicating metastatic lesions, multifocal liver lesions with both benign and malignant histopathologic findings, and comorbidities. Regarding the study population, no significant differences in age at diagnosis were identified among the groups with benign lesions, malignant liver lesions, and controls (P = .6302). In addition, no significant differences in sex were found among the groups (P = .6967).
However, body weight was significantly different among the HCC, benign liver disease, and control groups (P = .0125). 
| Size of HCC and completeness of excision after surgery
All dogs with HCC underwent complete surgical resection. Based on computed tomography results, the transverse diameter of HCC size ranged from 2.5 to 12.9 cm, with a median of 6.2 cm.
| PFAA concentrations
A comparison of the PFAA concentrations among the dogs with HCC, benign liver disease, and controls is presented in Table 1 . The concentrations of a single plasma amino acid (glutamic acid) were significantly different among the dogs with benign liver disease, HCC, and the control dogs (Table 1) . Specifically, the plasma concentrations of glutamic acid were significantly higher in dogs with benign and malignant liver lesions than in the control group (P < .0001). However, no significant difference in PFAA profiles were identified between dogs with HCC and those with benign liver lesions (P > .05).
Correlation analysis identified no significant correlations among PFAA concentrations, serum liver enzyme activities, and lesion size in dogs with HCC (P > .05). Abbreviations: AAAs, aromatic amino acids; BCAAs, branched-chain amino acids; BTR, branched-chain amino acids to tyrosine ratio; TAAs, total amino acids.
concentrations 3 to 6 months after surgical resection for HCC were not significantly different from those obtained before surgical resection (P > .05).
| DISCUSSION
We investigated the utility of changes in PFAA profiles as diagnostic biomarkers for HCC in dogs. Although we determined that plasma glutamic acid concentrations were significantly higher in dogs with HCC compared to healthy dogs, no significant differences were found between the PFAA profiles of HCC dogs and those with benign liver disease. In addition, plasma PFAA concentrations were not correlated with liver enzyme activities or lesion size in dogs with HCC.
Metabolites, including amino acids, can be altered in both neoplastic tissues 23, 24 and plasma. 7, [10] [11] [12] [13] [14] [15] [16] 18 Alterations in amino acid profiles and protein metabolism can reflect the effect of pathogenic changes because tumor development and growth require amino acids for protein synthesis, and both local and circulating amino acids are critical sources of metabolic fuel, leading to an increase in the mass of the affected tissue. To assess changes in protein metabolism after liver tumor resection, we investigated PFAA profiles 3 to 6 months after surgical treatment. We chose these time points because evidence in humans indicates that quality of life after liver resection returns to baseline at 3 months, with progressive and sustained improvements at 6 months. 36, 37 Therefore, the period between 3 and 6 months after surgery may be a reasonable time point for assessing improvements in PFAA concentrations after surgery. However, we did not find signifi- In conclusion, we found that increased plasma glutamic acid concentrations may involve or be a consequence of a liver mass lesion.
However, PFAA profiles of dogs with HCC could not be distinguished from those of dogs with benign liver diseases. In addition, postoperative glutamic acid concentrations of dogs with HCC did not improve after surgical resection compared to preoperative concentrations.
These results indicate that PFAA profiles may not be specific diagnostic biomarkers for detecting HCC in dogs. Additional studies with a larger population of dogs should be conducted to confirm our results.
